2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - 343-345
Technology and Procedures, Omics Technologies, Cell Expansion, Emerging Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Biological Processes, Immune Mechanism, Metabolism, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human
PAPER

280 T cell-specific delivery and genomic site-specific integration results in potent in vivo CAR T generation in models of hematological malignancies and non-human primates

Connor A. Tsuchida, PhD, Abdullah M. Syed, PhD2, Jonas L. Fowler, PhD3, Miranda H. Meeuwsen, PhD4, Thomas J. Gardner, PhD5, Justy Gomez Guagua6, Isha Ukani7, Ayesha Shabbir8, Cloelia DeCioccio9, Steven Long10, Nathan H. Kipniss, PhD11, June Dense12, Itzia Zaleta-Linares13, Phil Storm, PhD14, Cole Ingamells15, Alex Qu16, Mildred J. Unti, PhD17, Juan E. Hurtado Koolik, PhD18, Eleazar DeAlmeida19, Ben Cook20, Anastasiia Kamenska, PhD21, Paul Westberg22, James B. Whitney, PhD23, Jennifer R. Hamilton, PhD24
1 Azalea Therapeutics, Berkeley, California, United States
2 Azalea Therapeutics, Berkeley, California, United States
3 Azalea Therapeutics, Berkeley, California, United States
4 Azalea Therapeutics, Berkeley, California, United States
5 Azalea Therapeutics, Berkeley, California, United States
6 Azalea Therapeutics, Berkeley, California, United States
7 Azalea Therapeutics, Berkeley, California, United States
8 Azalea Therapeutics, Berkeley, California, United States
9 Azalea Therapeutics, Berkeley, California, United States
10 Azalea Therapeutics, Berkeley, California, United States
11 Azalea Therapeutics, Berkeley, California, United States
12 Azalea Therapeutics, Berkeley, California, United States
13 Azalea Therapeutics, Berkeley, California, United States
14 Azalea Therapeutics, Berkeley, California, United States
15 Azalea Therapeutics, Berkeley, California, United States
16 Azalea Therapeutics, Berkeley, California, United States
17 Azalea Therapeutics, Berkeley, California, United States
18 Azalea Therapeutics, Berkeley, California, United States
19 Azalea Therapeutics, Berkeley, California, United States
20 Azalea Therapeutics, Berkeley, California, United States
21 Azalea Therapeutics, Berkeley, California, United States
22 Azalea Therapeutics, Berkeley, California, United States
23 Boston College, Chestnut Hill, Massachusetts, United States
24 Azalea Therapeutics, Berkeley, California, United States

Introduction: Ex vivo chimeric antigen receptor (CAR) T cell therapies have been transformative in the treatment of some cancers, but still lack consistent durability and remain inaccessible due to their complex and expensive manufacturing process. While emerging in vivo CAR T cell therapies promise some solutions, they also present new challenges related to durability, cell-type specificity, and genomic integration site-specificity. Here, we present a novel in vivo platform to generate TRAC-CAR T cells via cell-specific delivery and genomic site-specific integration, resulting in therapeutic potency in humanized mouse models of leukemia and multiple myeloma, as well as in non-human primates (NHPs).

Methods: Azalea’s platform generates CAR T cells in vivo via CRISPR-mediated homology-directed repair for site-specific integration of a CAR transgene. CD3-targeted enveloped delivery vehicles (EDVs) deliver Cas9 to generate a double-stranded break at the TRAC gene. Simultaneously, a T cell-tropic AAV (AAV-T) delivers a promoterless CAR transgene flanked by TRAC homology arms. This dual vector approach enables precise genomic integration of the CAR gene for T cell-restricted expression from the endogenous TRAC promoter, a clinically validated strategy.

Immunodeficient mice were engrafted with human PBMCs and tumors followed by intravenous (IV) vector administration. Efficacy was evaluated in both NALM6 and OPM2 models of leukemia and multiple myeloma, respectively. In vivo TRAC-CAR T cell generation, tumor burden, and survival were measured. Additionally, we assessed feasibility in immunocompetent NHPs using a previously validated anti-CD20-4-1BBz CAR to enable assessment of TRAC-CAR T cell generation and targeting of CD20+ B cells after a single IV dose without pre-treatment, pre-conditioning, or lymphodepletion. 

Results: In mice, we observed dose-dependent generation of CD19-targeted TRAC-CAR T cells and complete NALM6 tumor clearance, even after tumor rechallenge at day 60. Simply changing the AAV transgene enabled in vivo generation of BCMA-targeted TRAC-CAR T cells, which were capable of full OPM2 tumor clearance in a humanized mouse model of multiple myeloma. Genomic analyses of in vivo engineered TRAC-CAR T cells revealed a single genomic insertion site, confirming the specificity and potential safety of this approach.

In vivo TRAC-CAR T cell generation was further demonstrated in 10 NHPs. All animals (10/10) demonstrated deep CD20+ B cell reduction (>90%) in the peripheral blood, with 9/10 of the animals at the highest dose levels demonstrating complete CD20+ B cell aplasia. B cell aplasia correlated with TRAC-CAR T cell generation, which peaked at 41% of all peripheral T cells. CD20+ B cell clearance also occurred beyond the peripheral blood, including in lymph nodes and bone marrow. Complete lymph node clearance was supported by abrogation of germinal center architecture via immunohistochemistry. While prophylactic tocilizumab (anti-IL-6R) was initially administered as a precaution, general tolerability in initial animals prompted the removal of any pre-treatment in the final 3 NHPs, which did not result in any safety issues. 

Conclusions: Azalea’s modular in vivo TRAC-CAR T cell platform shows durable potency against hematologic tumors in humanized mouse models of leukemia and multiple myeloma. It also achieves complete B cell aplasia in the peripheral blood and tissues of immune-intact NHPs, a testament to the depth of clearance achievable with this approach. In addition to the enhanced efficacy, in vivo TRAC-CAR T cells also displayed a unique safety profile. Next-generation sequencing confirmed uniform on-target genomic integration, eliminating the possibility of insertional oncogenesis, and dosing of the vectors was well tolerated in NHPs even without any pre-treatment. The depth of depletion and genomic specificity of in vivo TRAC-CAR T cell engineering offer efficacy and safety benefits over transient or randomly integrating in vivo platforms. Together, these differentiated features support development of a one-time, lymphodepletion-free in vivo CAR T cell therapy for cancer and beyond.

Connor A. Tsuchida, PhD: No relevant conflicts of interest to declare.